Published in Blood Weekly, June 1st, 2006
Clinical revenues alone increased 84% from 2005's first quarter. In fact, clinical sales have grown 48% in the current six months compared to the previous six months.
Cylex Inc. also noted that its flagship product, ImmuKnow, the first and only FDA-cleared cellular assay for measuring and managing the health of a patient's immune system, has significantly expanded its customer base in the organ transplant market. The ImmuKnow assay is now being...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.